|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 31/137 | (2013.01) | ||
| A61K 31/137 | (2006.01) | ||
| A61K 31/365 | (2013.01) | ||
| A61K 31/437 | (2013.01) | ||
| A61K 31/365 | (2006.01) | ||
| A61K 31/505 | (2013.01) | ||
| A61K 31/437 | (2006.01) | ||
| A61K 31/505 | (2006.01) | ||
| A61K 31/52 | (2013.01) | ||
| A61K 31/52 | (2006.01) | ||
| A61K 31/65 | (2013.01) | ||
| A61K 31/65 | (2006.01) | ||
| A61K 31/704 | (2013.01) | ||
| A61K 31/704 | (2006.01) | ||
| A61K 31/706 | (2013.01) | ||
| A61K 31/706 | (2006.01) | ||
| A61K 31/7064 | (2013.01) | ||
| A61K 31/7064 | (2006.01) | ||
| A61K 31/711 | (2013.01) | ||
| A61K 31/711 | (2006.01) | ||
| A61K 31/712 | (2013.01) | ||
| A61K 31/712 | (2006.01) | ||
| A61K 39/39558 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 16/2803 | (2013.01) | ||
| A61K 31/513 | (2013.01) | ||
| A61K 31/713 | (2013.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 2968536 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14718255.4 |
| Date of filing the European patent application | 2014-03-13 | |
| (97) | Date of publication of the European application | 2016-01-20 |
| (45) | Date of publication and mention of the grant of the patent | 2023-06-28 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/025989 |
| Date | 2014-03-13 |
| (87) | Number | WO 2014/160183 |
| Date | 2014-10-02 |
| (30) | Number | Date | Country code |
| 201361779587 P | 2013-03-13 | US |
| (72) |
ROBERTS, David, D. , US
SOTO PANTOJA, David, R. , US
|
| (73) |
The United States of America, as represented by
The Secretary, Department of Health and Human
Services ,
National Institutes of Health
Office of Technology Transfer
6011 Executive Boulevard
Suite 325
MSC 7660, Bethesda, MD 20852-7660,
US
|
| (54) | METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY |
| METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY |